Abdul Mannan: Advancing VWF Activity Testing Beyond VWF:RCo in Clinical Laboratories
Abdul Mannan, Consultant Hematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“Your VWF activity assay might be giving you the wrong answer.
And that wrong answer changes everything downstream.
VWF:RCo has been the workhorse of VWD testing for decades.
But here’s what the data actually shows:
- VWF:RCo imprecision sits around 9%. GPIb-based assays? Around 3.2%.
- Ristocetin-sensitive polymorphisms can falsely lower the activity:Ag ratio. That’s not biology. That’s assay noise.
- In diverse populations, this creates a predictable disadvantage. The same patient, different ethnicity, different result. That’s an equity problem.
Why does this matter so much?
The VWF activity result sits at the centre of the subtype algorithm. I
f that number drifts, everything drifts with it:
- Type 1 patients get pushed into a Type 2 work-up
- Unnecessary multimers, RIPA, genetics referrals follow
- DDAVP decisions and perioperative plans change
- Borderline cases get missed entirely
VWF:GPIbM offers a way out.
No ristocetin dependence.
No polymorphism distortion.
92% Type 2 sensitivity. 85.1% Type 1 specificity. Same 0.70 activity:Ag ratio threshold. Same diagnostic logic.
The message is simple: modernise the assay, preserve the pathway.
Both BSH 2024 and ASH/ISTH 2021 guidelines point the same direction.
But this isn’t just a reagent swap.
It’s a quality programme.
- Validation
- Reporting language
- Clinical education
- Post-go-live review
All need to land together.
I built an interactive guide to walk laboratories through this transition step by step.
- Assay comparison
- Decision algorithms
- Implementation framework
- Rhe evidence behind each choice
All in one place.
Has your lab made this switch yet?
What held you back, or what pushed you forward?”
Other posts featuring Abdul Mannan on Hemostasis Today.
-
Mar 14, 2026, 16:26Rida Fatima: When The Body’s Most Vital Production Unit Stops Working
-
Mar 14, 2026, 16:16Martin Haluzík: Metabolic Risk Factors and Therapeutic Opportunities in Cardiovascular Disease
-
Mar 14, 2026, 16:10Raffaella Colombatti: Proud to Have Authored the New Lancet Seminar on Sickle Cell Disease
-
Mar 14, 2026, 16:05Simon Senanu: D-Dimer – A Small Fragment with Big Clinical Significance
-
Mar 14, 2026, 15:53Ney Carter: Key Advances in the 2026 ACC/AHA Guideline on the Management of Dyslipidemia
-
Mar 14, 2026, 15:45Nicole Odofin: The First Blood Drive Event at Channel 4
-
Mar 14, 2026, 15:41Michael Makris: Romiplostim Use Allows More Chemotherapy to Be Delivered on Time
-
Mar 14, 2026, 15:40Jecko Thachil: Anticoagulation in Patients With Metabolic-Associated Fatty Liver Disease
-
Mar 14, 2026, 15:37Lorenz Räber: New Insights Into Silent Plaque Ruptures in AMI Patients